[Gaucher disease: A review].
Nguyen Y, Stirnemann J, Belmatoug N.
Rev Med Interne. 2019 May;40(5):313-322. doi: 10.1016/j.revmed.2018.11.012. Epub 2019 Jan 11.
Gaucher disease, state of the art and perspectives.
Camou F, Berger MG.
J Intern Med. 2025 Sep;298(3):155-172. doi: 10.1111/joim.20114. Epub 2025 Jul 3.
[Gaucher disease].
Nguyen Y, Stirnemann J, Belmatoug N.
Rev Prat. 2020 Apr;70(4):416-420.
Gaucher disease.
Guggenbuhl P, Grosbois B, Chalès G.
Joint Bone Spine. 2008 Mar;75(2):116-24. doi: 10.1016/j.jbspin.2007.06.006. Epub 2007 Aug 31.
Gaucher disease.
Beutler E.
Blood Rev. 1988 Mar;2(1):59-70. doi: 10.1016/0268-960x(88)90009-4.
Gaucher disease.
Ali MA, Saleh FM, Das K, Latif T.
Mymensingh Med J. 2011 Jul;20(3):490-2.
The clinical management of Type 2 Gaucher disease.
Weiss K, Gonzalez A, Lopez G, Pedoeim L, Groden C, Sidransky E.
Mol Genet Metab. 2015 Feb;114(2):110-122. doi: 10.1016/j.ymgme.2014.11.008. Epub 2014 Nov 14.
Gaucher disease type 3: Classification of the chronic neuronopathic variant informed by genotype in a phenotypically diverse cohort.
Donald A, Jones SA, Hughes DA, Church HJ; GAUCHERITE Consortium; Cox TM.
Genet Med. 2025 Sep;27(9):101502. doi: 10.1016/j.gim.2025.101502. Epub 2025 Jun 18.
Glucocerebrosidase (Gaucher disease).
Beutler E, Gelbart T.
Hum Mutat. 1996;8(3):207-13. doi: 10.1002/(SICI)1098-1004(1996)8:3<207::AID-HUMU2>3.0.CO;2-6.
A review of type 3 Gaucher disease: unique neurological manifestations and advances in treatment.
Zhong W, Li D, Fei Y, Hong P.
Acta Neurol Belg. 2024 Aug;124(4):1213-1223. doi: 10.1007/s13760-024-02493-1. Epub 2024 Feb 28.
